Why Does Factor XIII Only Need Monthly Infusions?
At a Glance
Factor XIII requires only monthly infusions because it has a long biological half-life of 11 to 14 days. Its unique molecular structure protects it from rapid breakdown in the bloodstream, allowing a single infusion to maintain safe trough levels and prevent bleeding for about four weeks.
In this answer
4 sections
If you have Factor XIII (FXIII) deficiency, you might have noticed that your treatment schedule is much less frequent than those of people with other bleeding disorders, like hemophilia. While someone with hemophilia might need an infusion of clotting factor several times a week, you typically only need one every four weeks. The reason for this difference comes down to a concept called biological half-life.
Understanding Biological Half-Life
Your body naturally breaks down and clears substances from your blood over time. The biological half-life is the amount of time it takes for exactly half of a specific substance to be cleared from your bloodstream [1]. A longer half-life means the substance stays in your body longer before you need more of it.
Factor XIII vs. Other Clotting Factors
Factor XIII naturally survives in the blood for a very long time compared to other clotting factors. Its half-life is approximately 11 to 14 days [1][2][3]. In contrast, standard Factor VIII—the clotting factor missing in Hemophilia A—has a half-life of only 8 to 12 hours [1][2][3]. Standard Factor IX, missing in Hemophilia B, lasts about 18 to 24 hours [1][2][3].
Because of this rapid breakdown, people with hemophilia must replace their clotting factors very frequently to keep their levels high enough to prevent bleeding [2]. However, because Factor XIII lasts so long, a single infusion typically provides enough factor to protect you for about four weeks [1][2].
Why Does Factor XIII Last So Long?
Factor XIII has a unique structure that helps protect it from being cleared away quickly. It circulates in the blood as a complex made of two different parts, or “subunits,” called A and B [4][5]. The B subunits act like a protective shield around the catalytic A subunits. This shield stabilizes the Factor XIII molecule and prevents your body from breaking it down rapidly [4][5].
Maintaining Your “Trough Level”
The main goal of your infusion schedule (also called prophylaxis) is to ensure your Factor XIII level never drops below a certain minimum amount needed to prevent spontaneous bleeding [6]. This lowest point, measured right before your next infusion, is called your trough level [7][6][8].
- Target Levels: Your doctor sets a specific target percentage for your trough level to ensure adequate hemostasis (clot stability) [9][6].
- Topping Off: By getting your infusion typically every 4 weeks, you are “topping off” your Factor XIII before your trough level drops too low, ensuring your blood can always form stable clots [7][6][8].
- Safety First: Because individual clearance rates vary, always follow the specific schedule prescribed by your hematologist. If you notice signs of delayed bleeding, such as unexplained bruising or oozing, toward the end of your cycle, contact your care team.
Common questions in this guide
Why do I only need Factor XIII infusions once a month?
What is a trough level in Factor XIII treatment?
Why does Factor XIII last so long in the body?
What should I do if I notice bleeding right before my next infusion is due?
Questions for Your Doctor
5 questions
- •What specific target trough level are we aiming for with my infusions?
- •How often will we test my blood to verify my trough levels are staying in our target range?
- •What should I do if I miss an infusion or am a few days late due to travel or scheduling conflicts?
- •Should we adjust my infusion schedule if I have upcoming dental work or minor surgery?
- •Am I receiving a plasma-derived or recombinant Factor XIII product, and how does that affect my long-term treatment plan?
Questions for You
3 questions
- •Do I notice any increased bruising or minor bleeding symptoms in the days immediately leading up to my next scheduled infusion?
- •How well does my current infusion schedule fit into my lifestyle, and are there recurring scheduling conflicts?
- •Am I confident in my ability to recognize the signs of a delayed bleeding episode?
References
References (9)
- 1
Recombinant factor XIII prophylaxis is safe and effective in young children with congenital factor XIII-A deficiency: international phase 3b trial results.
Kerlin BA, Inbal A, Will A, et al.
Journal of thrombosis and haemostasis : JTH 2017; (15(8)):1601-1606 doi:10.1111/jth.13748.
PMID: 28581691 - 2
Factor XIII Deficiency: A Review of Clinical Presentation and Management.
Pelcovits A, Schiffman F, Niroula R
Hematology/oncology clinics of North America 2021; (35(6)):1171-1180 doi:10.1016/j.hoc.2021.07.009.
PMID: 34607717 - 3
Safety and effectiveness of recombinant factor XIII-A2 in congenital factor XIII deficiency: Real-world evidence.
Poulsen LH, Kerlin BA, Castaman G, et al.
Research and practice in thrombosis and haemostasis 2022; (6(2)):e12628 doi:10.1002/rth2.12628.
PMID: 35243202 - 4
Sustained depletion of FXIII-A by inducing acquired FXIII-B deficiency.
Strilchuk AW, Meixner SC, Leung J, et al.
Blood 2020; (136(25)):2946-2954 doi:10.1182/blood.2020004976.
PMID: 32678423 - 5
An international collaborative study to assign value for Total Factor XIII-B Subunit Antigen to the WHO 1st International Standard for Factor XIII Plasma, (02/206): Communication from the ISTH SSC Subcommittee on Factor XIII and Fibrinogen.
Raut S, Katona É, Riches-Duit A, et al.
Journal of thrombosis and haemostasis : JTH 2022; (20(2)):525-531 doi:10.1111/jth.15596.
PMID: 34784091 - 6
Acquired FXIII Deficiency is Associated with High Morbidity.
Duque P, Chasco-Ganuza M, Ortuzar A, et al.
Thrombosis and haemostasis 2022; (122(1)):48-56 doi:10.1055/a-1481-2733.
PMID: 33851388 - 7
Minimal factor XIII activity level to prevent major spontaneous bleeds.
Menegatti M, Palla R, Boscarino M, et al.
Journal of thrombosis and haemostasis : JTH 2017; (15(9)):1728-1736 doi:10.1111/jth.13772.
PMID: 28688221 - 8
Factor XIII Concentrate Mitigates Hemorrhage in Pediatric Extracorporeal Membrane Oxygenation Support With Acquired Factor XIII Deficiency.
Fujita J, Ankola AA, Saini A, et al.
ASAIO journal (American Society for Artificial Internal Organs : 1992) 2025; doi:10.1097/MAT.0000000000002625.
PMID: 41361917 - 9
Congenital factor XIII deficiency: comprehensive overview of the FranceCoag cohort.
Bouttefroy S, Meunier S, Milien V, et al.
British journal of haematology 2020; (188(2)):317-320 doi:10.1111/bjh.16133.
PMID: 31414482
This information explaining Factor XIII infusion schedules is for educational purposes only. Always consult your hematologist before making changes to your prophylaxis routine or if you experience unexpected bleeding.
Get notified when new evidence is published on Factor XIII Deficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.